ETRADE Capital Management LLC reduced its stake in shares of Amgen (NASDAQ:AMGN) by 9.6% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 10,447 shares of the medical research company’s stock after selling 1,111 shares during the period. ETRADE Capital Management LLC’s holdings in Amgen were worth $1,781,000 as of its most recent SEC filing.
Other institutional investors also recently bought and sold shares of the company. Patten Group Inc. grew its holdings in shares of Amgen by 1,151.5% during the 3rd quarter. Patten Group Inc. now owns 27,859 shares of the medical research company’s stock valued at $389,000 after acquiring an additional 25,633 shares in the last quarter. LVM Capital Management Ltd. MI lifted its stake in shares of Amgen by 0.9% in the 4th quarter. LVM Capital Management Ltd. MI now owns 82,987 shares of the medical research company’s stock valued at $14,431,000 after purchasing an additional 780 shares during the last quarter. Pennsylvania Trust Co lifted its stake in shares of Amgen by 1.0% in the 4th quarter. Pennsylvania Trust Co now owns 97,619 shares of the medical research company’s stock valued at $16,976,000 after purchasing an additional 1,003 shares during the last quarter. Modera Wealth Management LLC lifted its stake in shares of Amgen by 1.3% in the 4th quarter. Modera Wealth Management LLC now owns 26,252 shares of the medical research company’s stock valued at $4,565,000 after purchasing an additional 331 shares during the last quarter. Finally, Sheaff Brock Investment Advisors LLC lifted its stake in shares of Amgen by 18.6% in the 4th quarter. Sheaff Brock Investment Advisors LLC now owns 43,099 shares of the medical research company’s stock valued at $7,495,000 after purchasing an additional 6,753 shares during the last quarter. Institutional investors and hedge funds own 86.24% of the company’s stock.
Several research firms recently issued reports on AMGN. Mizuho set a $200.00 price objective on shares of Amgen and gave the company a “buy” rating in a research note on Tuesday, May 15th. ValuEngine lowered shares of Amgen from a “buy” rating to a “hold” rating in a research note on Monday, April 2nd. Barclays reduced their price objective on shares of Amgen from $190.00 to $180.00 and set an “equal weight” rating for the company in a research note on Thursday, April 5th. Atlantic Securities lowered shares of Amgen from an “overweight” rating to a “neutral” rating and set a $187.01 price objective for the company. in a research note on Monday, February 5th. Finally, Zacks Investment Research lowered shares of Amgen from a “buy” rating to a “hold” rating in a research note on Tuesday, April 17th. Two analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and ten have given a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $191.70.
Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, April 24th. The medical research company reported $3.47 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.24 by $0.23. The firm had revenue of $5.55 billion during the quarter, compared to analyst estimates of $5.44 billion. Amgen had a net margin of 9.67% and a return on equity of 35.80%. The business’s revenue was up 1.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.15 EPS. equities analysts forecast that Amgen will post 13.71 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 8th. Stockholders of record on Thursday, May 17th will be given a dividend of $1.32 per share. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.99%. The ex-dividend date of this dividend is Wednesday, May 16th. Amgen’s dividend payout ratio is currently 41.97%.
Amgen declared that its Board of Directors has approved a share buyback plan on Thursday, February 1st that authorizes the company to buyback $10.00 billion in shares. This buyback authorization authorizes the medical research company to reacquire shares of its stock through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its shares are undervalued.
In other news, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction dated Thursday, April 12th. The shares were sold at an average price of $172.68, for a total transaction of $263,337.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 4,575 shares of company stock valued at $818,208 in the last ninety days. 0.19% of the stock is owned by company insiders.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.